• Please select a language£º
  • ÖÐÎÄ
  • English
  • News

    National Hotline£º0531-88086701 Shandong Xinchuang biological science and Technology Co Ltd
    Tel: 0531-88086701
    Address: Ji'nan high tech Zone, Han Yu Valley A2-3 7 storey building
    Address: Ji'nan city high tech Zone Port three northbound Ji'nan Valley No. 1 building B room 2206
    Refractory cancer of the first immunotherapy 3 clinical success
    Release time£º 2016-11-14 Views£º 27
    Gastric cancer is the fifth most common malignant tumor in the world, with more than 950 thousand new patients each year. Moreover, gastric cancer is the third major cause of cancer related deaths, the annual report of about 720000 cases of deaths. Gastric cancer is more common in men than in women, and the average age at diagnosis is 69 years. Although the five year survival rate of patients with gastric cancer was 30.4%, the survival rate of patients with metastatic or diffuse gastric cancer decreased dramatically to 5%. Although chemotherapy in treatment of surgery can not be advanced or recurrent gastric cancer showed reduced partial efficacy in tumor volume, but in this deterioration still exist significant unmet medical needs in case.

    Opdivo is a procedural death -1 (PD-1) immune checkpoint inhibitor, designed to use the body's own immune system to help restore the body's anti-tumor immune response. By using the body's own immune system against cancer, Opdivo has become an important therapeutic option for many types of cancer. In July 2014, Opdivo became the world's first approved PD-1 immune checkpoint inhibitor. Opdivo is currently in the United States, the European Union and Japan and other 57 countries to obtain approval. In October 2015, the Opdivo BMS and Yervoy combination program became the first to obtain regulatory approval for the treatment of metastatic melanoma immune oncology treatment portfolio, has been approved in the United States and the European Union and other 47 countries.

    ONO-4538-12 is in Japan, South Korea and Taiwan and other countries and regions of the multicenter, double-blind, randomized, placebo-controlled phase 3 clinical trial is to assess Opdivo in the operation efficacy and safety in patients with resection of advanced or recurrent gastric carcinoma, these refractory patients group also included gastrointestinal tract ward cancer, they do not tolerate to standard treatment. In the present study, Opdivo 3mg/kg or placebo was administered every 2 weeks until disease progression or discontinuation due to unacceptable toxicity.

    "Advanced or recurrent gastric cancer patients have a poor prognosis," commented Dr. Namouni Fouad, head of the Squibb Bristol-Myers development in the Department of oncology. At present, there is no standard treatment plan for patients who are not tolerate or respond to standard chemotherapy. According to the results of the ONO-4538-12 study, Opdivo is now the first to be shown to be able to provide benefits to the patient population of immune tumor agents."
    Copyright © Shandong Xinchuang biological science and Technology Co Ltd Tel£º0531-88086701 email£º1428795281@qq.com